Next Issue
Volume 5, December
Previous Issue
Volume 5, April
 
 

Clin. Transl. Neurosci., Volume 5, Issue 2 (September 2021) – 9 articles

  • Issues are regarded as officially published after their release is announced to the table of contents alert mailing list.
  • You may sign up for e-mail alerts to receive table of contents of newly released issues.
  • PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.
Order results
Result details
Section
Select all
Export citation of selected articles as:
58 pages, 410 KiB  
Conference Report
Abstracts of the 2021 Annual Virtual Meeting of the Swiss Society of Neurosurgery, September 16–17, 2021
by Raphael Guzman
Clin. Transl. Neurosci. 2021, 5(2), 19; https://doi.org/10.3390/ctn5020019 - 15 Sep 2021
Viewed by 3423
Abstract
On behalf of Swiss Society of Neurosurgery together with Association of neurosurgical nursing staff Switzerland, we are pleased to present the Abstracts of the 2021 Annual Meeting, that was held virtually from 16–17 September 2021. Fifty-one (51) abstracts were selected for presentation as [...] Read more.
On behalf of Swiss Society of Neurosurgery together with Association of neurosurgical nursing staff Switzerland, we are pleased to present the Abstracts of the 2021 Annual Meeting, that was held virtually from 16–17 September 2021. Fifty-one (51) abstracts were selected for presentation as oral presentations and forty (40) abstracts were selected as poster presentations. We congratulate all the presenters on their research work and contribution Full article
18 pages, 505 KiB  
Review
Could New Generations of Sensors Reshape the Management of Parkinson’s Disease?
by Oleg S. Levin, Olga V. Iakovleva, Irina I. Coloman and Anastasia V. Kuzmina
Clin. Transl. Neurosci. 2021, 5(2), 18; https://doi.org/10.3390/ctn5020018 - 13 Sep 2021
Cited by 2 | Viewed by 3329
Abstract
Parkinson's disease (PD) is a chronic neurologic disease that has a great impact on the patient’s quality of life. The natural course of the disease is characterized by an insidious onset of symptoms, such as rest tremor, shuffling gait, bradykinesia, followed by improvement [...] Read more.
Parkinson's disease (PD) is a chronic neurologic disease that has a great impact on the patient’s quality of life. The natural course of the disease is characterized by an insidious onset of symptoms, such as rest tremor, shuffling gait, bradykinesia, followed by improvement with the initiation of dopaminergic therapy. However, this “honeymoon period” gradually comes to an end with the emergence of motor fluctuations and dyskinesia. PD patients need long-term treatments and monitoring throughout the day; however, clinical examinations in hospitals are often not sufficient for optimal management of the disease. Technology-based devices are a new comprehensive assessment method of PD patient’s symptoms that are easy to use and give unbiased measurements. This review article provides an exhaustive overview of motor complications of advanced PD and new approaches to the management of the disease using sensors. Full article
Show Figures

Figure 1

10 pages, 604 KiB  
Article
Management of Acute Demyelinating Attacks in the Pediatric Population: A Swiss Consensus Statement
by Seline Hofer, Florian Bauder, Andrea Capone Mori, Andrew Chan, Patricia Dill, Stéphanie Garcia-Tarodo, Barbara Goeggel Simonetti, Annette Hackenberg, Judith Kalser, Oliver Maier, Regula Schmid, Susi Strozzi, Sandra Bigi and on behalf of the “Medico Scientific Advisory Board” of the Swiss Multiple Sclerosis Society
Clin. Transl. Neurosci. 2021, 5(2), 17; https://doi.org/10.3390/ctn5020017 - 10 Sep 2021
Viewed by 3589
Abstract
Background and methods: Acquired demyelinating syndromes (ADS) encompass distinct entities and occur in approximately 1/100,000 children. While the use of high dose intravenous corticosteroids is well-established, agreement on steroid taper and type of second line therapy is lacking. A comprehensive, unified and standardized [...] Read more.
Background and methods: Acquired demyelinating syndromes (ADS) encompass distinct entities and occur in approximately 1/100,000 children. While the use of high dose intravenous corticosteroids is well-established, agreement on steroid taper and type of second line therapy is lacking. A comprehensive, unified and standardized treatment approach is crucial in the management of patients with rare diseases. Therefore, this study performed from July 2018 to June 2020 aimed at developing a national consensus on the management of ADS in the pediatric population using the Delphi approach. Consensus was defined as agreement in >75%. Designated Neuropediatricians with an expertise in the management of pediatric neuroinflammatory diseases in all university and cantonal hospitals of Switzerland were included. The response rate was 100%. Results: High-dose i.v. methylprednisolone (20–30 mg/kg/die for 5 days) is the first line treatment irrespective of the distinct entity of the ADS. An oral steroid taper is recommended in acute demyelinating encephalomyelitis (ADEM) and in neuromyelitis optica spectrum disorder (NMO-SD). However, in the latter more in the sense of bridging. The choice of second line treatment depends on the entity of ADS: in optic neuritis (ON) and ADS due to relapsing remitting multiple sclerosis, first line treatment should be repeated, whereas plasma exchange is recommended in NMO-SD, ADEM and transverse myelitis. Conclusions: A national guideline allowing for a more unified approach in the management of pediatric ADS will enhance future research in this field, making data more comparable. The definition of inadequate treatment response to first line therapy remains a challenge and requires future research. Full article
Show Figures

Figure 1

17 pages, 925 KiB  
Review
Cluster Headache Pathophysiology—A Disorder of Network Excitability?
by Heiko Pohl, Peter S. Sandor, Lars Michels and Andreas R. Gantenbein
Clin. Transl. Neurosci. 2021, 5(2), 16; https://doi.org/10.3390/ctn5020016 - 09 Sep 2021
Cited by 2 | Viewed by 3734
Abstract
Patients’ accounts of cluster headache attacks, ictal restlessness, and electrophysiological studies suggest that the pathophysiology involves Aδ-fibre nociceptors and the network processing their input. Continuous activity of the trigeminal autonomic reflex throughout the in-bout period results in central sensitization of these networks in [...] Read more.
Patients’ accounts of cluster headache attacks, ictal restlessness, and electrophysiological studies suggest that the pathophysiology involves Aδ-fibre nociceptors and the network processing their input. Continuous activity of the trigeminal autonomic reflex throughout the in-bout period results in central sensitization of these networks in many patients. It is likely that several factors force circadian rhythmicity upon the disease. In addition to sensitization, circadian changes in pain perception and autonomic innervation might influence the excitability of the trigeminal cervical complex. Summation of several factors influencing pain perception might render neurons vulnerable to spontaneous depolarization, particularly at the beginning of rapid drops of the pain threshold (“summation headache”). In light of studies suggesting an impairment of short-term synaptic plasticity in CH patients, we suggest that the physiologic basis of CH attacks might be network overactivity—similarly to epileptic seizures. Case reports documenting cluster-like attacks support the idea of distinct factors being transiently able to induce attacks and being relevant in the pathophysiology of the disorder. A sustained and recurring proneness to attacks likely requires changes in the activity of other structures among which the hypothalamus is the most probable candidate. Full article
(This article belongs to the Section Headache)
Show Figures

Figure 1

10 pages, 2203 KiB  
Review
Intracerebral Hemorrhage, Visual Hallucination and COVID-19: What Is the Connection? A Case-Related Review of the Literature on Peduncular Hallucinosis Following Intracerebral Hemorrhage
by Nicolas M. Nagysomkuti Mertse, Lisa Zenorini and René Müri
Clin. Transl. Neurosci. 2021, 5(2), 15; https://doi.org/10.3390/ctn5020015 - 12 Aug 2021
Cited by 1 | Viewed by 6619
Abstract
Previous publications have discussed the occurrence of intracerebral hemorrhages, hallucinations and psychosis in COVID-19 patients. In this article, we have reviewed the literature on the subject while depicting the case of a 63-year-old female patient who suffered from an intracerebral hemorrhage in the [...] Read more.
Previous publications have discussed the occurrence of intracerebral hemorrhages, hallucinations and psychosis in COVID-19 patients. In this article, we have reviewed the literature on the subject while depicting the case of a 63-year-old female patient who suffered from an intracerebral hemorrhage in the right basal ganglia and thalamus two weeks after a COVID-19 diagnosis and who developed a visual hallucinosis shortly after. We concluded that, while there may be a correlation between COVID-19 and hallucinations according to current literature, more research is yet needed to clarify. In our case, we rather interpreted the hallucinations in the context of a peduncular hallucinosis related to the intracerebral hemorrhage. We compared our patient’s lesion localization to other 15 reported cases of peduncular hallucinations following intracerebral hemorrhages reported on Pubmed. In summary, the lesions were localized in the pons in 52.9% of the cases, 17.7% were in the thalamus and/or the basal ganglia, 17.7% in the mesencephalon and respectively 5.8% in the temporal and occipital lobe. The distribution pattern we found is consistent with the previously proposed mechanism behind peduncular hallucinations. Full article
Show Figures

Figure 1

3 pages, 200 KiB  
Perspective
Position Statement on Anti-Dementia Medication for Alzheimer’s Disease by Swiss Stakeholders
by Giovanni B Frisoni, Jean-Marie Annoni, Stefanie Becker, Tim Brockmann, Markus Buerge, Jean-François Démonet, Dan Georgescu, Anton Gietl, Ulrich Hemmeter, Stefan Klöppel, Thomas Leyhe, Andreas U Monsch, Franco Rogantini, Delphine Roulet Schwab, Egemen Savaskan, Karl Schaller, Armin von Gunten and Gabriel Gold
Clin. Transl. Neurosci. 2021, 5(2), 14; https://doi.org/10.3390/ctn5020014 - 10 Aug 2021
Viewed by 2562
Abstract
The present document represents the position of Swiss health-care associations, clinical and research centers, research-supporting foundations, and the association Alzheimer Switzerland regarding the care of persons with dementia and Alzheimer’s disease. We claim that dementia is not part of normal aging but a [...] Read more.
The present document represents the position of Swiss health-care associations, clinical and research centers, research-supporting foundations, and the association Alzheimer Switzerland regarding the care of persons with dementia and Alzheimer’s disease. We claim that dementia is not part of normal aging but a disease developing more frequently in old age; early diagnosis and treatment of dementia is paramount; all patients with dementia have the right to receive state-of-the-art treatments; more intense information, education, and counseling on dementia are necessary; media should provide balanced and fair reporting of scientific discoveries on Alzheimer’s and dementia; all patients with dementia have the right to be treated; anti-dementia drugs should be used and accompanied by listening, compassion, and understanding. Full article
16 pages, 16655 KiB  
Review
NeuroTec Sitem-Insel Bern: Closing the Last Mile in Neurology
by Kaspar A. Schindler, Tobias Nef, Maxime O. Baud, Athina Tzovara, Gürkan Yilmaz, Gerd Tinkhauser, Stephan M. Gerber, Oriella Gnarra, Jan D. Warncke, Narayan Schütz, Samuel E. J. Knobel, Markus H. Schmidt, Paul Krack, Flavio Fröhlich, Raphael Sznitman, Simon Rothen and Claudio L. A. Bassetti
Clin. Transl. Neurosci. 2021, 5(2), 13; https://doi.org/10.3390/ctn5020013 - 22 Jul 2021
Cited by 10 | Viewed by 5306
Abstract
Neurology is focused on a model where patients receive their care through repeated visits to clinics and doctor’s offices. Diagnostic tests often require expensive and specialized equipment that are only available in clinics. However, this current model has significant drawbacks. First, diagnostic tests, [...] Read more.
Neurology is focused on a model where patients receive their care through repeated visits to clinics and doctor’s offices. Diagnostic tests often require expensive and specialized equipment that are only available in clinics. However, this current model has significant drawbacks. First, diagnostic tests, such as daytime EEG and sleep studies, occur under artificial conditions in the clinic, which may mask or wrongly emphasize clinically important features. Second, early detection and high-quality management of chronic neurological disorders require repeat measurements to accurately capture the dynamics of the disease process, which is impractical to execute in the clinic for economical and logistical reasons. Third, clinic visits remain inaccessible to many patients due to geographical and economical circumstances. Fourth, global disruptions to daily life, such as the one caused by COVID-19, can seriously harm patients if access to in-person clinical visits for diagnostic and treatment purposes is throttled. Thus, translating diagnostic and treatment procedures to patients’ homes will convey multiple substantial benefits and has the potential to substantially improve clinical outcomes while reducing cost. NeuroTec was founded to accelerate the re-imagining of neurology and to promote the convergence of technological, scientific, medical and societal processes. The goal is to identify and validate new digital biomarkers that can close the last mile in neurology by enabling the translation of personalized diagnostics and therapeutic interventions from the clinic to the patient’s home. Full article
Show Figures

Figure 1

1 pages, 156 KiB  
Editorial
Publisher’s Note: Clinical and Translational Neuroscience—A Swiss Journal for a Global Readership
by Peter Roth
Clin. Transl. Neurosci. 2021, 5(2), 12; https://doi.org/10.3390/ctn5020012 - 15 Jul 2021
Viewed by 2126
Abstract
In its 5th year of existence, the journal CLINICAL AND TRANSLATIONAL NEUROSCIENCE [...] Full article
2 pages, 174 KiB  
Editorial
Clinical and Translational Neuroscience: Time for a Change: “What’s Past Is Prologue”
by Claudio Lino Alberto Bassetti
Clin. Transl. Neurosci. 2021, 5(2), 11; https://doi.org/10.3390/ctn5020011 - 02 Jul 2021
Viewed by 2338
Abstract
The first issue of Clinical and Translational Neuroscience (CTN) (ISSN: 2514-183X) appeared in 2017 [...] Full article
Previous Issue
Next Issue
Back to TopTop